PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAsenapine
Saphris, Sycrest(asenapine)
Asenapine, Saphris, Secuado, Sycrest (asenapine) is a small molecule pharmaceutical. Asenapine was first approved as Saphris on 2009-08-13. It is used to treat bipolar disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1D, histamine H1 receptor, 5-hydroxytryptamine receptor 1E, and 5-hydroxytryptamine receptor 1A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
Asenapine, Saphris, Secuado
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Asenapine
Tradename
Company
Number
Date
Products
SECUADOHisamitsu PharmaceuticalN-212268 RX2019-10-11
3 products, RLD
Asenapine maleate
Tradename
Company
Number
Date
Products
SAPHRISAllerganN-022117 RX2009-08-13
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
asenapineANDA2025-02-25
saphrisNew Drug Application2025-01-31
secuadoNew Drug Application2025-01-30
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Asenapine, Secuado, Hisamitsu
118133642033-09-22DP
96874742033-07-25DP
100224452033-07-25DP
105831212033-07-25DPU-2763
108140022033-07-25DPU-2763
111233052033-07-25DP
Asenapine Maleate, Saphris, Allergan
77413582026-04-06DS, DPU-1064, U-1893, U-1960, U-1961, U-1962, U-1963, U-1966
80222282026-04-06DS, DP
ATC Codes
N: Nervous system drugs
N05: Psycholeptics
N05A: Antipsychotics
N05AH: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
N05AH05: Asenapine
HCPCS
No data
Clinical
Clinical Trials
58 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F201118121
Bipolar disorderD001714EFO_0000289F30.919212
Psychotic disordersD011618F20.81235
Paranoid schizophreniaD012563F20.022
Disorganized schizophreniaD012562F20.122
Mental disordersD001523EFO_0000677F91.9112
Bipolar and related disordersD00006810511
Treatment-resistant schizophreniaD00009066311
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnhedoniaD059445R45.8411
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAsenapine
INNasenapine
Description
(S,S)-asenapine is a 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole in which both of the stereocentres have S configuration. It is a conjugate base of a (S,S)-asenapine(1+). It is an enantiomer of a (R,R)-asenapine.
Classification
Small molecule
Drug classtricyclic compounds
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1
Identifiers
PDB
CAS-ID65576-45-6
RxCUI784649
ChEMBL IDCHEMBL3187365
ChEBI ID71255
PubChem CID163091
DrugBankDB06216
UNII IDJKZ19V908O (ChemIDplus, GSRS)
Target
Agency Approved
HTR2A
HTR2A
DRD2
DRD2
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Alternate
HTR1B
HTR1B
HTR1D
HTR1D
HRH1
HRH1
HTR1E
HTR1E
HTR1A
HTR1A
Organism
Homo sapiens
Gene name
HTR1B
Gene synonyms
HTR1DB
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1B
Protein synonyms
5-HT-1D-beta, 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled, S12, Serotonin 1D beta receptor, Serotonin receptor 1B
Uniprot ID
Mouse ortholog
Htr1b (15551)
5-hydroxytryptamine receptor 1B (P28334)
Variants
No data
Financial
Revenue by drug
$
£
Saphris Allergan
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Saphris Warner Chilcott
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Asenapine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,857 documents
View more details
Safety
Black-box Warning
Black-box warning for: Asenapine, Saphris, Secuado
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,305 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use